Clinical Trial Update: Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma [Phase 3]

View source ↗

Summary

This Phase 3 trial update evaluated safety and efficacy of Symbicort pMDI (with or without a spacer) in children aged 6–11 with asthma, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort pMDI (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-02-27